TXG

10x Genomics, Inc.

$69.89

+0.04% 2026-10-19

Healthcare

1M 3M 6M 1Y 2Y

TXGSPY

-7.0%

-8.8%

+61.7%

+184.2%

YTD

+328.5%

+490.8%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$9.1B

P/E (trailing)–

P/E (forward)911.6

52-week range11.87 – 102.81

Revenue growth (YoY, latest qtr)-12.7%

Dividend yield0.00%

Analyst consensusBuy (15)

Mean price target$77.00 (+10%)

Valuation & fundamentals

Bottom line

Leans expensive

Model read-out from the numbers below, not advice. Score -2 (DCF counts double).

▼DCF (base case)below the price by 84%

•Piotroski F-score5/9

▲Altman Z25.6 (safe)

•Analyst target+10% (15 analysts)

Discounted cash flow

Bear

-87%

growth -8% · disc. 14.0% · term. 2.0%

Base

$11

-84%

growth -3% · disc. 13.0% · term. 2.5%

Bull

$14

-81%

growth 0% · disc. 12.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 32% a year for 10 years.

Implied

+32%/yr

FCF, last 3 yrs

n/a

FCF, last 5 yrs

n/a

Revenue, last 3 yrs

+8%/yr

Revenue, last 5 yrs

+17%/yr

Same inputs as the DCF above: trailing free cash flow 0.1B, 13.0% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.99 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $0.08 vs trailing $-0.59. Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$34.4M

as of 2025-12-31

vs a year ago

+4%

YoY

× TTM revenue

0.06×

coverage

24-03

24-06

24-09

24-12

25-03

25-06

25-09

25-12

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

70.0%

Operating margin

-14.3%

FCF margin

19.7%

Net margin

-12.2%

Return on equity

-9.1%

Return on invested capital

-25.5%

Net debt / EBITDA

–

Current ratio

5.7×

Interest cover

29,461.3×

Cash conversion (OCF/NI)

–

Piotroski F-score 5/9 · last two fiscal years

✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✓ Gross margin improved✗ Asset turnover improved

Altman Z-score 25.6 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$77

+10%

Analysts

Buy

Range

$50–$110

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$642.8M	$-43.5M	$130.1M
2024	$610.8M	$-182.6M	$-5.7M
2023	$618.7M	$-255.1M	$-63.8M
2022	$516.4M	$-166.0M	$-165.3M
2021	$490.5M	$-58.2M	$-122.7M
2020	$298.8M	$-542.7M	$-254.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +7.6%.

Earnings

Next report: 2026-11-05 · during market · EPS est -0.02

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	-0.02	0.03	+258.4%
2026-05-07	-0.06	0.07	+219.2%
2026-02-12	-0.04	0.07	+276.2%
2025-11-06	-0.07	-0.02	+67.4%
2025-08-07	-0.08	0.48	+702.1%
2025-05-08	-0.29	-0.10	+64.9%
2025-02-12	-0.11	-0.14	-27.1%
2024-10-29	-0.26	-0.02	+94.1%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$151.0M	-12.6%
2026-03-31	$150.8M	–
2025-12-31	$166.0M	–
2025-09-30	$149.0M	–
2025-06-30	$172.9M	–

Analyst actions

TD Cowen

2026-10-13 · main

Hold → Hold
PT $70

Morgan Stanley

2026-10-13 · main

Equal-Weight → Equal-Weight
PT $70

Canaccord Genuity

2026-10-12 · main

Buy → Buy
PT $100

Barclays

2026-10-07 · main

Overweight → Overweight
PT $110

Leerink Partners

2026-09-29 · main

Market Perform → Market Perform
PT $90

Piper Sandler

2026-09-28 · main

Neutral → Neutral
PT $80

Insider trades

Suliman Shehnaaz

Director · 2026-09-22

SELL
$22.8K

Suliman Shehnaaz

Director · 2026-09-22

SELL
$48.8K

Suliman Shehnaaz

Director · 2026-09-22

SELL
$107.1K

Suliman Shehnaaz

Director · 2026-09-22

SELL
$185.4K

Suliman Shehnaaz

Director · 2026-09-22

SELL
$100.5K

Saxonov Serge